Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Perflutren
Drug ID BADD_D01734
Description Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.
Indications and Usage Used as an ultrasound contrast imaging in cardiology and radiology.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB00556
KEGG ID D01738
MeSH ID C042852
PubChem ID 6432
TTD Drug ID D0G5BK
NDC Product Code 71124-0016; 11994-011; 11994-017; 63946-0040; 65044-0040
UNII CK0N3WH0SR
Synonyms perflutren | octafluoropropane | C3F8-gas | perfluoropropane | MRX-115
Chemical Information
Molecular Formula C3F8
CAS Registry Number 76-19-7
SMILES C(C(F)(F)F)(C(F)(F)F)(F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Granulocytosis01.02.01.008--Not Available
Haematoma24.07.01.001--
Haemoglobin13.01.05.018--Not Available
Haemolysis01.06.04.002-
Head discomfort17.02.05.027-Not Available
Headache17.14.01.001-
Hyperhidrosis08.01.03.028; 23.02.03.004-
Hypersensitivity10.01.03.003-
Hypertension24.08.02.001-
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hyperventilation22.02.01.006; 19.01.02.004-Not Available
Hypoaesthesia23.03.03.081; 17.02.06.023-Not Available
Hypotension24.06.03.002-
Hypoxia22.02.02.003-
Immune system disorder10.02.01.001--Not Available
Influenza like illness08.01.03.010--
Injection site extravasation12.07.03.002; 08.02.03.002-Not Available
Injection site pain08.02.03.010; 12.07.03.011--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Leukocytosis01.02.01.002--
Leukopenia01.02.02.001--Not Available
Lip swelling07.05.04.005; 23.04.01.007; 10.01.05.005-Not Available
Loss of consciousness17.02.04.004-Not Available
Lung disorder22.02.07.001-Not Available
Lymphadenopathy01.09.01.002--Not Available
Malaise08.01.01.003-
Menopausal symptoms21.02.02.002--Not Available
Monocytosis01.02.01.004--Not Available
Muscle spasms15.05.03.004-
Musculoskeletal pain15.03.04.007-
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages